Office of the Secretary; Notice of Meeting, 11844 [2024-03106]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
11844
Federal Register / Vol. 89, No. 32 / Thursday, February 15, 2024 / Notices
Goal 1: Enhance discovery and
advance HIV science through
fundamental research.
Description: Fundamental research
seeks to expand understanding of the
biological, physiological, interpersonal,
and social-structural mechanisms of
HIV—i.e., how it operates as a virus and
as an infectious disease pandemic—at
the molecular, cellular, individual,
community, and population level. This
understanding provides the foundation
for the development of safe, effective,
and scalable tools to prevent, treat, and
ultimately cure HIV infection, as well as
reduce the risk and impact of comorbid
conditions and co-occurring infections.
Fundamental research includes
theoretical, pre-clinical, and
methodological research across
scientific disciplines.
Goal 2: Advance the development and
assessment of novel interventions for
HIV prevention, treatment, and cure.
Description: Knowledge gleaned from
fundamental, pre-clinical, and
translational research to inform clinical
trials and other intervention studies to
test the most promising products, tools,
or strategies for HIV prevention,
treatment, and cure and management of
its complications. Rigorous randomized
control trials, observational studies, and
other methodologies assess biological,
behavioral, and social outcomes of
novel interventions, as well as their
feasibility, acceptability, effectiveness,
and scalability in differing populations
and across the lifespan.
Goal 3: Optimize public health impact
of HIV discoveries through translation,
dissemination, and implementation of
research findings.
Description: As HIV prevention,
treatment, and cure interventions are
shown to be efficacious, their findings
must be translated to inform practice
and to connect with communities and
the general public in order to maximize
their public health impact.
Implementation research can identify
how best to facilitate effective
adaptation, uptake, integration, and
scale-up of evidence-based HIV
interventions. Information-sharing
through community partnerships,
research collaborations, and
dissemination activities can amplify the
impact of research and promote health
equity.
Goal 4: Build research workforce and
infrastructure capacity to enhance
sustainability of HIV scientific
discovery.
Description: Continued progress in
HIV science and its application requires
robust support for research tools,
computational resources,
instrumentation, data and physical
VerDate Sep<11>2014
18:36 Feb 14, 2024
Jkt 262001
infrastructure, and workforce
development, particularly in
institutions that serve underrepresented
or high HIV burden populations or that
historically have been underfunded in
the United States and globally. Such
enhanced capacity-strengthening efforts
will promote diversity and inclusion in
the HIV research workforce.
Respondents are also invited to share
comments on the new framework.
Responses to this RFI Notice are
voluntary. The submitted information
will be reviewed by NIH staff and may
be made available to the public.
Submitted information will not be
considered confidential. This request is
for information and planning purposes
and should not be construed as a
solicitation or as an obligation of the
federal government or the NIH. No
awards will be made based on responses
to this Request for Information. The
information submitted will be analyzed
and may be used in reports or
presentations. Those who respond are
advised that the NIH is under no
obligation to acknowledge receipt of
your comments or provide comments on
your submission. No proprietary,
classified, confidential and/or sensitive
information should be included in your
response. The NIH and the government
reserve the right to use any nonproprietary technical information in any
future solicitation(s).
Dated: February 5, 2024.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2024–03122 Filed 2–14–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Name of Committee: Muscular Dystrophy
Coordinating Committee.
Date: March 18, 2024.
Time: 12:00 p.m. to 4:00 p.m. ET.
Agenda: The purpose of this meeting is to
bring together committee members,
representing government agencies, patient
advocacy groups, other voluntary health
organizations, and patients and their families
to update one another on progress relevant to
the Action Plan for the Muscular Dystrophies
and to coordinate activities and discuss gaps
and opportunities leading to better
understanding of the muscular dystrophies,
advances in treatments, and improvements in
patients’ and their families’ lives. The agenda
for this meeting will be available on the
MDCC website: https://www.mdcc.nih.gov/.
Registration: To register, please go to:
https://roseliassociates.zoomgov.com/
meeting/register/vJItc-6hrTsuHDKRDbVsTHLsMoFRuqyoRw#/registration.
Webcast Live: https://videocast.nih.gov/.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Glen Nuckolls, Ph.D.,
Program Director, National Institute of
Neurological, Disorders and Stroke (NINDS),
NIH, 6001 Executive Blvd., Bethesda, MD
20892, 301–496–5876, MDCC@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Anyone from the public can attend the
meeting virtually via the NIH Videocasting
website (https://videocast.nih.gov). Please
continue checking these websites, in addition
to the committee website listed below, for the
most up to date guidance as the meeting date
approaches.
More information can be found on the
Muscular Dystrophy Coordinating Committee
website: https://mdcc.nih.gov/.
Dated: February 9, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–03106 Filed 2–14–24; 8:45 am]
Office of the Secretary; Notice of
Meeting
BILLING CODE 4140–01–P
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Muscular Dystrophy
Coordinating Committee (MDCC).
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting can be accessed
from the NIH Videocast at the following
link: https://videocast.nih.gov/.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 89, Number 32 (Thursday, February 15, 2024)]
[Notices]
[Page 11844]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-03106]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Muscular Dystrophy
Coordinating Committee (MDCC).
The meeting will be held as a virtual meeting and will be open to
the public as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting, should notify the Contact Person listed below in
advance of the meeting. The meeting can be accessed from the NIH
Videocast at the following link: https://videocast.nih.gov/.
Name of Committee: Muscular Dystrophy Coordinating Committee.
Date: March 18, 2024.
Time: 12:00 p.m. to 4:00 p.m. ET.
Agenda: The purpose of this meeting is to bring together
committee members, representing government agencies, patient
advocacy groups, other voluntary health organizations, and patients
and their families to update one another on progress relevant to the
Action Plan for the Muscular Dystrophies and to coordinate
activities and discuss gaps and opportunities leading to better
understanding of the muscular dystrophies, advances in treatments,
and improvements in patients' and their families' lives. The agenda
for this meeting will be available on the MDCC website: https://www.mdcc.nih.gov/.
Registration: To register, please go to: https://roseliassociates.zoomgov.com/meeting/register/vJItc-6hrTsuHDK-RDbVsTHLsMoFRuqyoRw#/registration.
Webcast Live: https://videocast.nih.gov/.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Glen Nuckolls, Ph.D., Program Director, National
Institute of Neurological, Disorders and Stroke (NINDS), NIH, 6001
Executive Blvd., Bethesda, MD 20892, 301-496-5876, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Anyone from the public can attend the meeting virtually via the
NIH Videocasting website (https://videocast.nih.gov). Please
continue checking these websites, in addition to the committee
website listed below, for the most up to date guidance as the
meeting date approaches.
More information can be found on the Muscular Dystrophy
Coordinating Committee website: https://mdcc.nih.gov/.
Dated: February 9, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-03106 Filed 2-14-24; 8:45 am]
BILLING CODE 4140-01-P
